Novo Nordisk reported that ziltivekimab failed to reduce major cardiovascular events in the Phase 3 ZEUS trial, despite lowering inflammation through IL-6 inhibition. The Denmark-based company tested the drug in more than 6,300 patients with cardiovascular disease, chronic kidney disease
US policymakers are debating whether the US Treasury should extend outbound investment controls to biotechnology transactions involving China. John Stanford, executive director at Incubate, warned that broad restrictions could affect licensing, investment and development partnerships as Chinese companies play a
Chinese biotech licensing deals have become a major source of global drug pipelines. Pharmaceutical Executive reported more than $43 billion in licensing commitments during the first five months of 2026, while US lawmakers proposed broader scrutiny of biotechnology investments linked
A July 29, 2026 Pharmaceutical Technology feature by Christian Olsen examines a recurring failure in biologics R&D: systems preserve experimental results while losing the reasoning behind them. As candidates move from discovery into lead optimization, CMC and scale-up, missing context
GSK announced a £400 million plan on July 28, 2026, to establish a 300,000-square-foot global R&D centre on the Cambridge Biomedical Campus. The company plans to move more than 1,000 UK scientists to Cambridge, leave its Stevenage R&D site through
The FDA proposed a new registration pathway on July 10, 2026, for distributed manufacturing networks that operate through a hub-and-spoke model. If finalized, the FDA distributed manufacturing rule would let qualifying networks register as one establishment instead of registering every
Argenx has agreed to acquire Forte Biosciences for approximately $2.2 billion, placing a major bet on FB102 before its key Phase 2 celiac disease results arrive. The deal gives argenx a first-in-class anti-CD122 antibody with early signals in celiac disease
Capricor Therapeutics shares plunged about 65% on Monday after FDA reviewers questioned whether deramiocel benefits patients with Duchenne muscular dystrophy. The agency released its assessment before a July 29 advisory committee meeting. Although Capricor calls HOPE-3 Phase 3 study positive,
Summit Therapeutics and China-based Akeso have reported new Western data for ivonescimab, their PD-1/VEGF-targeting lung cancer antibody. The findings suggest that the drug’s efficacy may extend beyond Chinese patients. However, the case highlights a wider regulatory problem: strong Phase 3
Novogene Europe has expanded its single-cell RNA sequencing capability at the Cambridge Omics Centre in the UK. The new service brings advanced 10x Genomics Chromium workflows closer to academic, biotech and biopharma researchers. While the expansion can accelerate biomarker research